OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in
Long Island, New York with facilities in Colorado, New Jersey and the United ...
Agensys, Inc., a subsidiary of Astellas Pharma Inc. is developing a pipeline of
therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor
May 17, 2010 ... Astellas Pharma (4503.T), Japan's No. 2 drugmaker, agreed to buy U.S. biotech
OSI Pharmaceuticals OSIP.O for $4 billion in cash in a ...
Roche and OSI Pharmaceuticals to pay $67m to resolve claims they
misrepresented Tarceva effectiveness, diverting patients from first-line treatments
May 14, 2013 ... Staying up-to-date has never been simpler. Sign up for the free GenePool
newsletter today! Reshaping Research Framework to Enhance the ...
As of May, 2013, OSI Pharmaceuticals Inc. went out of business. OSI
Pharmaceuticals Inc. offers oncology drug discovery and translational research
OSI Pharmaceuticals (Nasdaq: OSIP) and Gilead Sciences (Nasdaq: GILD) today
announced that they have signed an agreement, valued at up to $200 million ...
OSI Pharmaceuticals Announces Acceptance of a Tarceva(R) Supplemental New
Drug. Application in Pancreatic Cancer for Review by the U.S. Food and Drug ...
Previous Close, N/A. Open, N/A. Bid, N/A x N/A. Ask, N/A x N/A. Day's Range, N/A
- N/A. 52 Week Range, undefined - undefined. Volume, N/A. Avg. Volume, N/A ...
Jun 9, 2010 ... TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced
today that the company has completed its acquisition of OSI ...